Navigation Links
uniQure Initiates Phase I in Acute Intermittent Porphyria
Date:12/11/2012

AMSTERDAM, December 11, 2012 /PRNewswire/ --

uniQure B.V., a leader in the field of human gene therapy, today announced the start of its Phase I clinical trial in acute intermittent porphyria (AIP) with the treatment of the first patient. The study is conducted under the aegis of the AIPGENE consortium, a pan-European collaboration funded in part by the European Commission's Seventh Framework Program with the aim to develop a gene therapy for the treatment of AIP, a rare and devastating disease caused by mutations in the porphobilinogen deaminase gene (PBGD). AIP can be life-threatening and the long-term effects include irreversible nerve damage, liver cancer and kidney failure. uniQure was granted orphan drug designation for the treatment of AIP in 2009 from the European Medicines Agency.

"The start of the AIP Phase I study marks the first of four programs that will enter clinical trials over the next 12 months," says Jörn Aldag, CEO of uniQure.  "After AIP we expect clinical trials to be initiated in Parkinson's disease, hemophilia B, and Sanfilippo B. After many years of building and developing our capabilities and competencies, and the approval in November of Glybera for LPLD as the first gene therapy in the Western world, we are highly motivated to expedite the clinical development of our other advanced gene therapies."

About the AIP Phase I study

The Phase I will enroll eight patients with severe AIP at two centers: the Clinical University of Navarra, Pamplona, Spain, and the 12 de Octubre University Hospital,, Madrid, Spain. The study's primary objective is the assessment of safety and determination of the maximum tolerated dose.  Secondary objectives include tolerability of treatment, pharmacokinetics, changes in the levels of surrogate markers of activity including porphobilinogen (PBG) and delta-aminolevulinic acid (ALA), and assessment of symptom control, neuro-psychological changes and quality of life. All pa
'/>"/>

SOURCE uniQure B.V.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. uniQure Appoints Hans Christian Rohde Chief Commercial Officer
2. uniQure Licenses RNA Interference Technology to Advance Huntingtons Disease Program
3. Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
4. The Acute Liver Failure Study Group Initiates Phase 2a Study of OCR-002 for Treatment of Acute Liver Failure after Acetaminophen Overdose
5. Isis Pharmaceuticals Initiates Phase 1b/2a Study Of ISIS-SMNRx In Patients With Spinal Muscular Atrophy
6. Isis Initiates Phase 2 Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
7. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
8. Healthpoint Biotherapeutics Initiates Phase III Study of Unique Investigational Cell-Based Therapy for Venous Leg Ulcers
9. New Jersey Health Foundation Initiates Program To Spur Innovative Research
10. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
11. ImmusanT Initiates Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , August 3, 2015 ... 2015 market research with 2020 forecasts as well ... healthcare and medical devices intelligence collection of its ... simulation market with 2020 forecasts spread across 164 ... with 170 tables and figures is now available ...
(Date:8/3/2015)... , Aug. 3, 2015 Par Pharmaceutical ... conference call on Friday, August 7, 2015 at 9:00 ... the second quarter ended June 30, 2015.  Par is ... to the public in its filings with the Securities ... available on its website by following the instructions at ...
(Date:8/3/2015)... Aug. 3, 2015 OmniSeq, LLC today ... to the OmniSeq SM Genomic Network.  Recently, ... Institute (RPCI) and announced it was making available ... physician-driven, collaborative approach to genomic diagnostics that provides ... Institute is a rapidly expanding, multidisciplinary cancer care ...
Breaking Medicine Technology:Medical Simulation Market to see 14% CAGR to 2019 2Medical Simulation Market to see 14% CAGR to 2019 3Medical Simulation Market to see 14% CAGR to 2019 4Medical Simulation Market to see 14% CAGR to 2019 5Medical Simulation Market to see 14% CAGR to 2019 6OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3
... Jan. 10, 2011 CoreLab Partners, Inc , ... Inc and Medifacts International, has launched a new advanced ... are pleased to announce the release of our proprietary ... development continuum by offering sponsors advanced technologies and integrated ...
... Underwriters Laboratories (UL), a world ... release of a white paper that addresses the current ... equipment. The white paper, "Home Healthcare Equipment: An ... highlights the unique challenges for manufacturers with the U.S. ...
Cached Medicine Technology:CoreLab Partners Launches Advanced Imaging Application 2CoreLab Partners Launches Advanced Imaging Application 3UL White Paper Examines Key Implications of Growing Home Healthcare Industry 2
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma Solutions, the leading ... consumer health products, today welcomed the announcement by OPKO Health that the US ... a new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... amputation , AUGUST 3, 2015 – Since winning a South by Southwest® (SXSW®) ... Impossible – an organization whose mission is to develop technology for the sake ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... Leadership ® and Navigant Center for Healthcare Research and Policy Analysis show widespread ... percent of respondents said they agreed or strongly agreed that the controversial law ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Modoc National Forest, to Ahjumawi Lava Springs, California’s northernmost and among its least ... largest untapped ground water aquifers, whose main outflow is at Ahjumawi Lava Springs, ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article from ... Cells Found to Release Natural Painkiller That Can Last 'For Five Weeks'" discusses ... the report, the new study showed that harvesting stem cell-rich bone marrow from the ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3
... , , , ... Translational Research and the California Institute for Quantitative Biomedical ... (UCSF) together with Collaborative Drug Discovery, Inc. (CDD) are ... will present at the 3rd Annual Collaborative Drug Discovery ...
... treatment? Cost versus efficacy? So go two of the ... his fellow researchers in the race to fight HIV ... especially among women and their young children. ... Palumbo, a Dartmouth Medical School professor of medicine and ...
... , BETHPAGE, N.Y., Sept. 15 ... research into better detection and treatment of pancreatic cancer, today ... Patrick Swayze,s life. , , Kerri ... death of beloved actor Patrick Swayze. His courageous, public battle ...
... , ELLICOT CITY, Md., Sept. 15 As ... public, doctors and medical staff are beginning to evaluate their practice ... investing in PC-based medical equipment. , , Medical ... practice. Doctors must use the same precision and care they give ...
... have spent ... since 2007 ... campaign contributions , , WASHINGTON, ... industries spent $126,430,438 over the first half of 2009 and $585,725,712 over the past two and a half years ...
... , , , ... Inc. (Pink Sheets: ASFX) (the Company) today announced the appointment ... as Senior Vice President and Director of Business Development of ... of the intellectual property formerly owned by Safeguard, which produces ...
Cached Medicine News:Health News:3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research to be Held October 1st 2Health News:3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research to be Held October 1st 3Health News:3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research to be Held October 1st 4Health News:Weighing costs, benefits of HIV treatments 2Health News:Weighing costs, benefits of HIV treatments 3Health News:The Lustgarten Foundation Says Patrick Swayze's Death Highlights the Need for Increased Research into Early Diagnosis and Treatment of Pancreatic Cancer 2Health News:More Doctors Diagnose PC as a Winner 2Health News:Insurance and HMO Industries Spend Nearly $700,000 Per Day to Kill Health Care Reform Measures 2Health News:American Scientific Resources, Inc. Welcomes Jason Roth 2
... Silver Wire Coil and helix provide ... buckling.,Unique Silver Wire Construction eliminates springback ... Tip is designed to provide a ... aesthetic result. ,Trimmable ends ...
... Prosthesis,The AMS DURA II ... of cobalt-chrome alloy strands ... gives patients what they ... positioning, cosmetic concealment and ...
... The AMS 650™ and 600M™ malleable ... many patientsespecially those with limited dexterity. These ... allows the patient to position them in ... make the penis rigid enough for sexual ...
... The AMS 700 Series is an advanced ... in the abdomen, a pump placed in the ... the corpora cavernosa. It closely simulates the look ... standard for innovative penile implant technology, the AMS ...
Medicine Products: